Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

Poly (ADP-ribose) polymerase inhibitor (PARPi)-based combination therapies are demonstrating efficacy in patients, however, identifying the right combination for the right patient remains a critical challenge. Thus, it is urgent to develop approaches able to identify patients likely to benefit from...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Labrie, Marilyne, Kim, Tae-Beom, Ju, Zhenlin, Lee, Sanghoon, Zhao, Wei, Fang, Yong, Lu, Yiling, Chen, Ken, Ramirez, Pedro, Frumovitz, Michael, Meyer, Larissa, Fleming, Nicole D., Sood, Anil K., Coleman, Robert L., Mills, Gordon B., Westin, Shannon N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2019
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6544405/
https://ncbi.nlm.nih.gov/pubmed/31191824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26947
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi